Dose optimization is essential to ensure that patients receive therapies that maximize efficacy while minimizing toxicity. Poor dose optimization can have negative consequences for patients, most notably, toxicities leading to poor quality of life, and inability to tolerate a given regimen. Although there has been some progress, dose optimization through randomized dose evaluation in oncology trials is not routinely conducted.
With FDA's Project Optimus initiative, the landscape of Phase I oncology trials is changing. In this webinar, IQVIA oncology experts will highlight major principles for dose optimization and review examples of recent FDA approvals that illustrate how investigation of dose- and exposure-response relationships and use of randomized dose trials can support dose optimization.
join this timely webinar and learn:
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
.svg){kind=icon}
